drugset / Trial / NCT01605370

Can Nebivolol Reverse Inappropriate Left Ventricular Mass in Hypertensive Patients?

NCT01605370

Phase 4 Terminated 1 enrolled Mayo Clinic Forest Laboratories · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate if a drug called nebivolol can reverse inappropriate left ventricular mass (LVM) when compared to the standard of care drug metoprolol.

Timeline

Start
2012-06
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Metoprolol Other / unclassified 50 mg
Subject Nebivolol Other / unclassified 2.5 mg

Indications